What We're Reading: Page 247
Industry reads hand-picked by our editors
Aug 08, 2018
-
Xconomy
With big Takeda deal at launch, can Ambys keep control of its future?
-
Bloomberg Opinion
Carl Icahn knows it's never too late to derail a deal
-
Boston Business Journal
As FDA decision looms, Alnylam triples Kendall footprint, plans to double staff
Aug 07, 2018
-
Los Angeles Times
Sorry about your Stage 3 cancer. Here's a bill for $21,000 in charges you thought were covered
-
CNN
At 18, she launched a biotech startup. Four years later, she's blazing a trail in the VC world
-
Reuters
Biotech entrepreneur Drayson plans to list new AI drug research firm
-
The Washington Post
She made a career out of studying the brain. Then hers veered off course.
Aug 06, 2018
-
The Wall Street Journal
How China is evolving from a maker of copycat medicines into a producer of complex drugs
-
NPR
How one family's fight with epilepsy led to the first marijuana-based pharmaceutical
-
Associated Press
Feds probe firm's ties to illegal pharma merchants
-
TechCrunch
Boston-area startups are on pace to overtake NYC venture totals
Aug 03, 2018
Aug 02, 2018
-
The New York Times
Trump finally picks a science adviser. And scientists? They seem relieved.
-
STAT
Did a blockbuster drug make hundreds gamble compulsively? A legal fight may decide what science can't confirm
-
Bloomberg
Facing wave of opioid lawsuits, drug companies sprinkle charity on hard-hit areas
-
The Washington Post
Childhood cancer survivors face ‘financial toxicity’
Aug 01, 2018
-
The New York Times
Justice Dept. investigating claims that drug companies funded terrorism in Iraq
-
The Wall Street Journal
Why Americans spend so much on health care — in 12 charts
-
Medical Marketing and Media
GSK digital leader brings tech flair
-
WBUR News
Price of HIV test falls, raising hopes In global AIDS fight
Jul 31, 2018
-
STAT
At Sanofi, a flu expert sees potential for improved vaccines
-
Reuters
Bayer hits back at new Netflix medical device documentary
-
The Korea Herald
Korea-made drugs nearing US FDA approval, pharma exports to rise
-
The New York Times
After doctors cut their opioids, patients turn to a risky treatment for back pain
Previous
